Author

V. Syrgkanis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:clinical cohort / trial· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Gilson· 1 shared A. Snyder· 1 shared C. Borgs· 1 shared D. F. Bajorin· 1 shared J. Chayes· 1 shared J. Rosenberg· 1 shared L. Mackey· 1 shared M. D. Leiserson· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Gilson

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit in Response to a PD-L1 Inhibitor

M. D. Leiserson, V. Syrgkanis, A. Gilson, M. Dudik, S. Gillett, J. Chayes, C. Borgs, D. F. Bajorin, J. Rosenberg, S. Funt, A. Snyder, L. Mackey

This paper develops a multifactorial model to predict T cell expansion and clinical benefit from PD-L1 inhibitors using clinical, tumor, and circulating features, showing improved accuracy over single biomarkers.

bioRxiv · Apr 10, 2018Cancer Biology